157 related articles for article (PubMed ID: 23579219)
21. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
[TBL] [Abstract][Full Text] [Related]
22. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
[TBL] [Abstract][Full Text] [Related]
25. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
26. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
27. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G; Cannita K; Di Giacomo D; Lamy A; Troncone G; Dal Mas A; Coletti G; Frébourg T; Sabourin JC; Tosi M; Ficorella C; Ricevuto E
BMC Med; 2012 Nov; 10():135. PubMed ID: 23136868
[TBL] [Abstract][Full Text] [Related]
29. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
30. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
[TBL] [Abstract][Full Text] [Related]
31. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
32. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
33. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
[TBL] [Abstract][Full Text] [Related]
34. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.
Pietrantonio F; Perrone F; Biondani P; Maggi C; Lampis A; Bertan C; Venturini F; Tondulli L; Ferrari D; Ricci V; Villa F; Barone G; Bianco N; Ghidini A; Bossi I; Fanetti G; Di Bartolomeo M; de Braud F
Cancer Biol Ther; 2013 Dec; 14(12):1098-103. PubMed ID: 24025413
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
36. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.
Qiu LX; Mao C; Zhang J; Zhu XD; Liao RY; Xue K; Li J; Chen Q
Eur J Cancer; 2010 Oct; 46(15):2781-7. PubMed ID: 20580219
[TBL] [Abstract][Full Text] [Related]
37. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations.
Liang YH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Hung JS; Tseng LH; Lin LI; Chang YL; Cheng AL; Yeh KH
Anticancer Res; 2015 Jul; 35(7):4207-14. PubMed ID: 26124380
[TBL] [Abstract][Full Text] [Related]
39. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
40. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]